213 related articles for article (PubMed ID: 18599182)
1. Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma.
Barber A; Zhang T; Megli CJ; Wu J; Meehan KR; Sentman CL
Exp Hematol; 2008 Oct; 36(10):1318-28. PubMed ID: 18599182
[TBL] [Abstract][Full Text] [Related]
2. Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells.
Barber A; Meehan KR; Sentman CL
Gene Ther; 2011 May; 18(5):509-16. PubMed ID: 21209626
[TBL] [Abstract][Full Text] [Related]
3. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
Zhang T; Barber A; Sentman CL
Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
[TBL] [Abstract][Full Text] [Related]
4. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment.
Barber A; Rynda A; Sentman CL
J Immunol; 2009 Dec; 183(11):6939-47. PubMed ID: 19915047
[TBL] [Abstract][Full Text] [Related]
5. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
Barber A; Zhang T; DeMars LR; Conejo-Garcia J; Roby KF; Sentman CL
Cancer Res; 2007 May; 67(10):5003-8. PubMed ID: 17510432
[TBL] [Abstract][Full Text] [Related]
6. Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.
Zhang T; Sentman CL
J Immunol; 2013 Mar; 190(5):2455-63. PubMed ID: 23355740
[TBL] [Abstract][Full Text] [Related]
7. Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection.
Lehner M; Götz G; Proff J; Schaft N; Dörrie J; Full F; Ensser A; Muller YA; Cerwenka A; Abken H; Parolini O; Ambros PF; Kovar H; Holter W
PLoS One; 2012; 7(2):e31210. PubMed ID: 22355347
[TBL] [Abstract][Full Text] [Related]
8. Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity.
Barber A; Sentman CL
J Immunol; 2009 Aug; 183(4):2365-72. PubMed ID: 19625653
[TBL] [Abstract][Full Text] [Related]
9. Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked.
von Lilienfeld-Toal M; Frank S; Leyendecker C; Feyler S; Jarmin S; Morgan R; Glasmacher A; Märten A; Schmidt-Wolf IG; Brossart P; Cook G
Cancer Immunol Immunother; 2010 Jun; 59(6):829-39. PubMed ID: 20024547
[TBL] [Abstract][Full Text] [Related]
10. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.
Zhang T; Lemoi BA; Sentman CL
Blood; 2005 Sep; 106(5):1544-51. PubMed ID: 15890688
[TBL] [Abstract][Full Text] [Related]
11. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
12. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways.
Zhang T; Barber A; Sentman CL
Cancer Res; 2007 Nov; 67(22):11029-36. PubMed ID: 18006849
[TBL] [Abstract][Full Text] [Related]
13. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
Fernández L; Metais JY; Escudero A; Vela M; Valentín J; Vallcorba I; Leivas A; Torres J; Valeri A; Patiño-García A; Martínez J; Leung W; Pérez-Martínez A
Clin Cancer Res; 2017 Oct; 23(19):5824-5835. PubMed ID: 28659311
[No Abstract] [Full Text] [Related]
14. Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.
Baumeister SH; Murad J; Werner L; Daley H; Trebeden-Negre H; Gicobi JK; Schmucker A; Reder J; Sentman CL; Gilham DE; Lehmann FF; Galinsky I; DiPietro H; Cummings K; Munshi NC; Stone RM; Neuberg DS; Soiffer R; Dranoff G; Ritz J; Nikiforow S
Cancer Immunol Res; 2019 Jan; 7(1):100-112. PubMed ID: 30396908
[TBL] [Abstract][Full Text] [Related]
15. T cells gene-engineered with DAP12 mediate effector function in an NKG2D-dependent and major histocompatibility complex-independent manner.
Teng MW; Kershaw MH; Hayakawa Y; Cerutti L; Jane SM; Darcy PK; Smyth MJ
J Biol Chem; 2005 Nov; 280(46):38235-41. PubMed ID: 16169855
[TBL] [Abstract][Full Text] [Related]
16. Potential therapeutic strategy for gastric cancer peritoneal metastasis by NKG2D ligands-specific T cells.
Liu X; Sun M; Yu S; Liu K; Li X; Shi H
Onco Targets Ther; 2015; 8():3095-104. PubMed ID: 26543378
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma.
Wu JY; Ernstoff MS; Hill JM; Cole B; Meehan KR
Cytotherapy; 2006; 8(2):141-8. PubMed ID: 16698687
[TBL] [Abstract][Full Text] [Related]
18. [Construction of NKG2D CAR-NK92 cells and its killing effect on multiple myeloma cells].
Long J; Zheng R; Ye S; Ke S; Duan D; Wei C; Gao J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Jul; 39(7):577-585. PubMed ID: 37403715
[TBL] [Abstract][Full Text] [Related]
19. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.
Spear P; Barber A; Rynda-Apple A; Sentman CL
Immunol Cell Biol; 2013 Jul; 91(6):435-40. PubMed ID: 23628805
[TBL] [Abstract][Full Text] [Related]
20. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition.
Song DG; Ye Q; Santoro S; Fang C; Best A; Powell DJ
Hum Gene Ther; 2013 Mar; 24(3):295-305. PubMed ID: 23297870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
